The Latest Breaking News from Zealand Pharma

Experimental Survodutide Cut Weight Up to 13.1% in Adults with Type 2 Diabetes in Boehringer's Phase 3 Trial

Survodutide cut weight by up to 13.1% in adults with type 2 diabetes in a company-funded trial. It is not approved, and 18% quit due to side effects.

Medical Daily · Oct 2

Lancet Publishes Full Petrelintide Trial: About 10% Weight Loss, Nausea in 20% as Amylin Drug Enters Phase 3

Full Phase 2 results for petrelintide in The Lancet show about 10% weight loss and nausea in 20%. What the experimental amylin drug means for patients.

Medical Daily · Oct 1

Why Zealand Pharma Shares Are Rising

Zealand Pharma A/S - ADR (NASDAQ: ZEAL) shares are trading higher by 17.01% at $13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital hyperinsulinism met the primary endpoint with statistical significance.

Benzinga · May 19, 2022

Recap: Zealand Pharma Q4 Earnings

  Zealand Pharma (NASDAQ:ZEAL) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 10, 2022

Zealand Pharma's Earnings Outlook

Zealand Pharma (NASDAQ:ZEAL) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts estimate that Zealand Pharma will report an earnings per share (EPS) of $-0.93.

Benzinga · Mar 9, 2022